Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

9 Jan 2008 07:00

Persimmon PLC09 January 2008 TRADING UPDATE - WEDNESDAY 9 JANUARY 2008 Persimmon plc announces the following trading update ahead of its PreliminaryResults to 31 December 2007, which will be announced on Tuesday 26 February2008. Despite experiencing more challenging trading conditions in the second half of2007, Persimmon expects to announce another strong set of results for the year.We have improved operating margins for the year through a combination of tightcost control, the delivery of further synergy savings from the Westburyacquisition and the benefits emerging from the successful development of ourstrategic land portfolio. This will deliver an increase in profit before tax for2007 in line with the mid range of analyst expectations. The Board confirms that, in line with its previous statement, it recommendspaying a minimum 10% increase in the dividend for the year ended 31 December2007 subject to shareholder approval at the Annual General Meeting in April2008. Since we reported our Interim Results on 21 August 2007, the market has beenmore difficult. Volumes have been impacted as lower consumer confidence and thetightening of credit markets reduced activity in the important Autumn period. Asa result we have achieved 15,905 legal completions during 2007, a reduction of5% against 2006 (16,701). However, sales prices have remained resilient during this period, although asanticipated at the time of our Interim Results, we have experienced an increasein incentives and marketing costs. Underlying price growth of our homes for sale was c. 3% during the year. Theaverage selling price of our homes increased to £189,558 (2006: £188,129). Thisincrease in average selling price has been achieved whilst at the same time wehave increased the proportion of affordable homes developed. During the period we were also increasingly selective with our land purchasesand continued to exercise tight control over our work in progress investment toensure that cash management remained robust. Our total landbank remains at asimilar level to last year and currently we own or control c. 79,000 (2006:80,085) plots for future development. Our balance sheet remains strong and cash flows are healthy, with gearing at theyear end of c. 31% (2006: 33%). Forward sales into 2008 were £603 million (December 2006: £701 million). Thislargely reflects the lower level of sales achieved over the last 3 months of2007 due to market uncertainties. Now that interest rates have changed directionand with the Spring selling period ahead of us we expect to experience anincrease in the level of activity over that achieved in the recent months. Weare operating from c. 7% more outlets than in January 2007 which should furthersupport our sales activity for the Spring season. It is too early in the New Year to predict exactly how the market will developover the next few months. However, we are confident that our focus on cashmanagement through these more challenging times will ensure that when the marketimproves we are well set to take advantage of it. We believe that the underlyingfundamentals for our industry remain intact and supportive. Details of our Results for 2007 and a future market update will be announced onTuesday 26 February 2008. For further information, please contact:Mike Farley, Group Chief ExecutiveMike Killoran, Group Finance Director Persimmon plcOn 9th January 2008: +44 (0) 20 7153 1570After this date: Tel: +44 (0) 1904 642 199 M: CommunicationsEdward Orlebar / Charlotte McMullenTel: +44 (0) 20 7153 1523 / 1549 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.